Survivorship: cognitive function, version 1.2014.

Denlinger CS, Ligibel JA, Are M, Baker KS, Demark-Wahnefried W, Friedman DL, Goldman M, Jones L, King A, Ku GH, Kvale E, Langbaum TS, Leonardi-Warren K, McCabe MS, Melisko M, Montoya JG, Mooney K, Morgan MA, Moslehi JJ, O'Connor T, Overholser L, Paskett ED, Raza M, Syrjala KL, Urba SG, Wakabayashi MT, Zee P, McMillian NR, Freedman-Cass DA, National Comprehensive Cancer Network
J Natl Compr Canc Netw. 2014 12 (7): 976-86

PMID: 24994918 · PMCID: PMC4465252 · DOI:10.6004/jnccn.2014.0094

Cognitive impairment is a common complaint among cancer survivors and may be a consequence of the tumors themselves or direct effects of cancer-related treatment (eg, chemotherapy, endocrine therapy, radiation). For some survivors, symptoms persist over the long term and, when more severe, can impact quality of life and function. This section of the NCCN Guidelines for Survivorship provides assessment, evaluation, and management recommendations for cognitive dysfunction in survivors. Nonpharmacologic interventions (eg, instruction in coping strategies; management of distress, pain, sleep disturbances, and fatigue; occupational therapy) are recommended, with pharmacologic interventions as a last line of therapy in survivors for whom other interventions have been insufficient.

Copyright © 2014 by the National Comprehensive Cancer Network.

MeSH Terms (16)

Adaptation, Psychological Benzhydryl Compounds Brain Neoplasms Central Nervous System Stimulants Cognition Disorders Fatigue Humans Methylphenidate Modafinil Occupational Therapy Pain Management Quality of Life Sleep Wake Disorders Survival Rate Treatment Outcome Wakefulness-Promoting Agents

Connections (1)

This publication is referenced by other Labnodes entities: